...
首页> 外文期刊>Revista da Sociedade Brasileira de Medicina Tropical >In vitro and in vivo antileishmanial activity of Artemisia annua L. leaf powder and its potential usefulness in the treatment of uncomplicated cutaneous leishmaniasis in humans
【24h】

In vitro and in vivo antileishmanial activity of Artemisia annua L. leaf powder and its potential usefulness in the treatment of uncomplicated cutaneous leishmaniasis in humans

机译:青蒿叶粉的体外和体内抗衰老活性及其在治疗人类单纯性皮肤利什曼病中的潜在用途

获取原文
           

摘要

INTRODUCTION: Cutaneous leishmaniasis (CL) is a tropical disease that affects millions of individuals worldwide. The current drugs for CL may be effective but have serious side effects; hence, alternatives are urgently needed. Although plant-derived materials are used for the treatment of various diseases in 80% of the global population, the validation of these products is essential. Gelatin capsules containing dried Artemisia annua leaf powder were recently developed as a new herbal formulation ( totum) for the oral treatment of malaria and other parasitic diseases. Here, we aimed to determine the usefulness of A. annua gel capsules in CL. METHODS: The antileishmanial activity and cytotoxicity of A. annua L. capsules was determined via in vitro and in vivo studies. Moreover, a preliminary evaluation of its therapeutic potential as antileishmanial treatment in humans was conducted in 2 patients with uncomplicated CL. RESULTS: Artemisia annua capsules showed moderate in vitro activity in amastigotes of Leishmania (Viannia) panamensis ; no cytotoxicity in U-937 macrophages or genotoxicity in human lymphocytes was observed. Five of 6 (83.3%) hamsters treated with A. annua capsules (500mg/kg/day) for 30 days were cured, and the 2 examined patients were cured 45 days after initiation of treatment with 30g of A. annua capsules, without any adverse reactions. Both patients remained disease-free 26 and 24 months after treatment completion. CONCLUSION: Capsules of A. annua L. represent an effective treatment for uncomplicated CL, although further randomized controlled trials are needed to validate its efficacy and safety.
机译:简介:皮肤利什曼病(CL)是一种热带疾病,影响着全球数百万的人。目前的CL药物可能有效,但有严重的副作用。因此,迫切需要替代方案。尽管在全球80%的人口中使用植物来源的材料来治疗各种疾病,但对这些产品的验证至关重要。含有干燥的蒿叶干粉的明胶胶囊最近被开发为一种新的草药制剂(totum),用于口服治疗疟疾和其他寄生虫病。在这里,我们旨在确定在CL中的A.annua凝胶胶囊的有效性。方法:通过体外和体内研究确定A. annua L.胶囊的抗疟疾活性和细胞毒性。此外,对2名单纯性CL患者进行了初步评价,以评价其作为抗衰老药物在人体中的治疗潜力。结果:青蒿胶囊在利什曼原虫(Viannia)panamensis的变形虫中显示出适度的体外活性。没有观察到U-937巨噬细胞的细胞毒性或人类淋巴细胞的遗传毒性。用A.annua胶囊(500mg / kg /天)治疗30天的6只仓鼠中有5只(53.3%)cured愈,开始用30g A. annua胶囊治疗后45天治愈了2位接受检查的患者不良反应。两名患者在完成治疗后26和24个月仍保持无病。结论:A. annua L.胶囊代表了一种简单的CL治疗方法,尽管还需要进一步的随机对照试验来验证其疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号